Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.
The feasibility, safety, and efficacy of prolonged, continuous, intravenous clindamycin therapy were retrospectively evaluated for 70 patients treated for bone and joint infections, 40% of whom were treated as outpatients. The median treatment duration was 40 days, the median daily clindamycin dose was 2,400 mg, and three moderate-grade adverse events occurred. The median serum clindamycin concentrations on days 3 to 14 and days 8 to 28 were 5 and 6.2 mg/liter, respectively; the median concentration was significantly lower (P < 0.02) in patients treated with rifampin (5.3 mg/liter) than in those not treated with rifampin (8.9 mg/liter). Among 53 patients with a median follow-up of 30 months (range, 24 to 53 months), 49 (92%) were considered cured (1 patient had a relapse, and 3 patients had reinfections).
Zeller
Valérie
V
Centre de Référence des Infections Ostéo-Articulaires, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d'Avron, Paris 75020, France. vzeller@hopital-dcss.org
Dzeing-Ella
Arnaud
A
Kitzis
Marie-Dominique
MD
Ziza
Jean-Marc
JM
Mamoudy
Patrick
P
Desplaces
Nicole
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001850:Bone Diseases, Infectious / Q000188:drug therapy*; D002981:Clindamycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015331:Cohort Studies; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012293:Rifampin / Q000494:pharmacology; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D012293:Rifampin